Search results
A new COVID variant is dominant in the US: What are its symptoms?
TODAY via Yahoo News· 2 days agoThe new "FLiRT" COVID-19 variants, including KP.3 and KP.2, are spreading in the United States. Will...
Bird flu tests are hard to get. How will we know when to sound the alarm?
NBC News via Yahoo News· 6 days agoTo become a pandemic, the H5N1 bird flu virus would need to spread from person to person. The...
Scientists use gene technology to develop possible antidote to black widow spider bite
United Press International via Yahoo News· 4 days agoIn severe cases, people might need hospitalization to treat high blood pressure, heart problems or...
New antivenom invented for black widow spider bites
Live Science via Yahoo News· 5 days agoIn all, the team identified 45 human antibodies that could do this, including one in particular, called MRU44-4-A1, which showed "outstandingly" high...
Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of...
Benzinga· 12 hours agoElectra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoFDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., June 9, 2024 TOKYO and CAMBRIDGE,
Carlyle Group Inc. Sells 64,263 Shares of QuidelOrtho Co. (NASDAQ:QDEL) Stock
ETF DAILY NEWS· 15 hours agoQuidelOrtho Co. (NASDAQ:QDEL – Get Free Report) major shareholder Carlyle Group Inc. sold 64,263 shares of QuidelOrtho stock in a transaction that occurred on Wednesday, June 12th. Following ...
Moderna says combination flu, COVID shot succeeds in study
BioPharma Dive via Yahoo Finance· 6 days agoIn Moderna’s study, mRNA-1083 was tested in two groups of 4,000 adults. In one, adults aged 65 years...
Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy
FierceBiotech· 4 days agoThe initial data drop assesses del-brax, a novel RNA therapeutic Avidity has dubbed an “antibody...
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
Barrons.com· 5 days ago“We believe having two players on the market is a win-win for both BIIB and LLY as there’d be more...